TRIANA Biomedicines
Aravind Prasad is a seasoned computational chemist with extensive experience in drug discovery and development across multiple prestigious organizations. Currently with TRIANA Biomedicines since February 2022, Aravind has previously held roles at Constellation Pharmaceuticals, Bristol Myers Squibb, Celgene, Avila Therapeutics, IndiScine Biosciences, and Biogen Idec, contributing significantly to the establishment of computational chemistry functions and innovative platforms. Aravind's expertise encompasses molecular dynamics, machine learning applications in cheminformatics, druggability assessments, and the integration of computational strategies into drug discovery programs. Aravind holds a Master’s degree in Bioinformatics from Northeastern University and a Bachelor’s degree in Electronics and Communications Engineering.
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.